Abstract and Introduction
Cannabidiol (CBD) oral solution, Epidiolex®, was approved by the Food and Drug Administration (FDA) on June 25, 2018 for the treatment of seizures associated with Lennox Gastaut syndrome (LGS) and Dravet syndrome in patients 2 years of age and older.[1,2] It was given Priority Review and Fast-Track designations by the FDA, as well as orphan drug status for its potential benefit in treating refractory seizures in patients with these syndromes. The approval of CBD reflects not only the scientific evidence supporting its role as add-on therapy, but also the growing support among the families of patients with LGS and Dravet syndrome.
Pediatr Pharm. 2018;24(11) © 2018 University of Virginia